Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics.

Neurotherapeutics

New York Medical College, Metropolitan Hospital, 1901 First Ave. Suite 7C5, New York, NY, 10029, USA.

Published: October 2015

Cannabis has been used for many medicinal purposes, including management of spasms, dystonia, and dyskinesias, with variable success. Its use for tetanus was described in the second century BCE, but the literature continues to include more case reports and surveys of its beneficial effects in managing symptoms of hyperkinetic movement disorders than randomized controlled trials, making evidence-based recommendations difficult. This paper reviews clinical research using various formulations of cannabis (botanical products, oral preparations containing ∆(9)-tetrahydrocannabinol and/or cannabidiol) and currently available preparations in the USA (nabilone and dronabinol). This has been expanded from a recent systematic review of cannabis use in several neurologic conditions to include case reports and case series and results of anonymous surveys of patients using cannabis outside of medical settings, with the original evidence classifications marked for those papers that followed research protocols. Despite overlap in some patients, dyskinesias will be treated separately from dystonia and chorea; benefit was not established beyond individual patients for these conditions. Tics, usually due to Tourettes, did respond to cannabis preparations. Side effects reported in the trials will be reviewed but those due to recreational use, including the dystonia that can be secondary to synthetic marijuana preparations, are outside the scope of this paper.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604174PMC
http://dx.doi.org/10.1007/s13311-015-0376-4DOI Listing

Publication Analysis

Top Keywords

dystonia dyskinesias
8
include case
8
case reports
8
cannabis
6
cannabis treatment
4
dystonia
4
treatment dystonia
4
dyskinesias tics
4
tics cannabis
4
cannabis medicinal
4

Similar Publications

Background: Bilateral deep brain stimulation (DBS) of subthalamic nucleus (STN) has demonstrated efficacy for ameliorating medication-refractory isolated dystonia. Nonetheless, the paucity of evidence regarding its long-term impact on quality-of-life (QoL) necessitates further investigation.

Objectives: This study aimed to elucidate the longitudinal effects of chronic STN stimulation on QoL in patients suffering from isolated dystonia.

View Article and Find Full Text PDF

Background: Dystonia is a common neurological hyperkinetic movement disorder that can be caused by mutations in anoctamin 3 (ANO3, TMEM16C), a phospholipid scramblase and ion channel. We previously reported patients that were heterozygous for the ANO3 variants S651N, V561L, A599D and S651N, which cause dystonia by unknown mechanisms.

Methods: We applied electrophysiology, Ca measurements and cell biological methods to analyze the molecular mechanisms that lead to aberrant intracellular Ca signals and defective activation of K channels in patients heterozygous for the ANO3 variants.

View Article and Find Full Text PDF

Engaging dystonia networks with subthalamic stimulation.

Proc Natl Acad Sci U S A

January 2025

Center for Brain Circuit Therapeutics, Department of Neurology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115.

Deep brain stimulation is an efficacious treatment for dystonia. While the internal pallidum serves as the primary target, recently, stimulation of the subthalamic nucleus (STN) has been investigated. However, optimal targeting within this structure and its surroundings have not been studied in depth.

View Article and Find Full Text PDF

Purpose Of This Research: To study the association between ICBs and LIDs and to assess the predictors of ICBs in this sample.

Methods: We intentionally evaluated 90 Brazilian PD patients younger than 60 in one evaluation that included the application of Questionnaire for Impulsive Compulsive Disorders - Current Short (QUIP-CS), Barratt Impulsive Scale-11 (BIS-11), Beck Depression Inventory-II (BDI-II), Unified Parkinson's Disease Rating Scale parts III and IV, Unified Dyskinesia Rating Scale (UDysRS), and a cognitive assessment.

Results: ICB group had a longer PD duration (8.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!